Abstract:Objective To investigate the inhibitory effect of soluble HLA-G1 (sHLA-G1) on the cytolytic function of NK-92, and the relation of sHLA-G1 receptors, ILT2 and KIR2DL4, to the inhibition. Methods ①Recombinant sHLA-G1 was obtained by prokaryotic expression and verified by Western blot. ②NK-92 cells were treated with the recombinant sHLA-G1 at 20 μg/ml for 10 or 30 min, and then added with, anti-HLA-G1/G5 mAb, anti-ILT2 Ab, and anti-KIR2DL4 mAb. NK-92 without treatment served as a positive control. The expression of sHLA-G1, ILT2, and KIR2DL4 on the surface of NK-92 cells was analyzed with flow cytometry. ③Human leukemia cells K562 was used as target cells and the NK-92cells treated with recombinants sHLA-G1 as the effecters. The effecters and target cells was co-cultured for 2 h at a ratio of 5:1. Then, flow cytometry was used to detect the death rate of K562 cells. Before the co-culture, the effecter, NK-92 cells were divided into two groups. In one group, the NK-92 was treated with 0, 10, or 20μg/ml recombinant sHLA-G1 for 30 min; and in the other group, it was first incubated with anti-ILT2 Ab, or anti-KIR2DL4 mAb, or both, for 30 min, and then co-cultured with 0, 10, or 20μg/ml recombinant sHLA-G1 for 30 min. Results ①The recombinant protein was verified as having a histidine tag by Western blot. ②Compared with the control, the positive rate of sHLA-G1 expression was significantly increased and that of the ILT2 and KIR2DL4 was significantly decreased in the NK-92 cells treated with 20 μg/ml recombinant sHLA-G1 for 30 min (P 0.05). ③After being co-cultured with 0, 10, or 20 μg/ml recombinant sHLA-G1-treated NK-92, the death rate of the K562 reached 39.79% ± 2.00%, 27.79% ± 0.75%, or 21.36% ± 0.67% (one-to-one compared, P 0.05). When the ILT2 was blocked, the death rate was 23.09% ± 1.63%, 21.13% ± 0.38%, and 18.42% ± 0.47% (one-to-one compared, P 0.05); and when the KIR2DL4 was blocked, it was 30.74% ± 0.44%, 26.03% ± 0.38%, 21.15% ± 0.35% (one-to-one compared, P 0.05). Conclusion sHLA-G1 can inhibit the cytolytic function of NK-92 by directly binding to ILT2 and KIR2DL4.

Effect of HLA-G5 Immune Checkpoint Molecule on the Expression of ILT-2, CD27, and CD38 in Splenic B cells

Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary

The HLA-G immune checkpoint: a new immuno-stimulatory role for the α1-domain-deleted isoform

The human immune checkpoint molecule, HLA-G2, induces tolerance in monocytes and dendritic cells via upregulation of PD-L1

HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies

HLA-G: A New Immune Checkpoint in Cancer?

HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease

Dimerization of soluble HLA-G by IgG-Fc fragment augments ILT2-mediated inhibition of T-cell alloresponse.

HLA-G Expressing Immune Cells in Immune Mediated Diseases

Soluble HLA-G, its diagnostic and prognostic value and potential target molecule for future therapy in cancer

Human Leukocyte Antigen-G Inhibits the Anti-Tumor Effect of Natural Killer Cells via Immunoglobulin-Like Transcript 2 in Gastric Cancer

HLA-G can be transfered via trogocytosis from leukemic cells to T cells in chronic lymphocytic leukemia

Role of HLA-G in Viral Infections

The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?

Soluble Hla-G Inhibits Myeloid Dendritic Cell Function In Hiv-1 Infection By Interacting With Leukocyte Immunoglobulin-Like Receptor B2

Interactions Between Shla-G1 and Its Receptors ILT2, and KIR2DL4 on NK-92 Cells

HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives

Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?

Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

HLA-G - evolvement from a trophoblast specific marker to a checkpoint molecule in cancer, a narrative review about the specific role in breast- and gynecological cancer

Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects